Compass Biotechnologies Inc (OTCMKTS: COBI) Comeback Gaining Momentum

Compass Biotechnologies Inc (OTCMKTS: COBI) is flying high ahead of its upgrade to OTC Pink Current Information Status. The company has worked round the clock to achieve the feat, on posting financial statements for the past three years as well as a detailed disclosure document.

COBI Catalysts And Share Price Value

In addition, the stock’s sentiments appear to have inched higher on the company confirming it is executing a national growth strategy. In a special letter to investors, the management reiterates that it has accrued lucrative niches in the cannabis industry set to fuel the next phase of growth.Through a well-thought business model, Compass Biotechnologies is able to provide land to cannabis growers and distributors at a lower cost thus its competitive edge in the industry.According to the Chief Executive Officer, Rick Shykora, Compass Biotechnologies is one of the most undervalued equities in the cannabis sector. COBI Daily ChartCompass Biotechnologies continues to languish near all-time lows after underperforming the past few years. With the stock currently languishing at the $0.0009 level, it would take groundbreaking catalysts for the stock to bottom out and take out the $0.01 psychological level.However, it appears the management is moving to reinvigorate Compass Biotechnologies prospects by reiterating long-term growth prospects.A bullish 2019 outlook should go a long way in triggering renewed investor interest in the stock as the company continues to accrue market share in niche sectors, in the cannabis industry.

About Compass Biotechnologies

Compass Biotechnologies casts itself as a development stage company focused on developing licenses for patents used in preventing and treating hepatitis B. In the recent past, the company has evolved to become a cannabis play as it seeks to pursue opportunities in the multi-billion industry. The company is currently engaged in the acquisition and leasing of real estate for use in the cannabis industry.

OTC Market Reporting Status

Compass Biotechnologies share price and market activity appear to have received a boost on the company securing an upgrade in the OTC marketplace. The OTC Pink Market has since upgraded the company’s reporting status.The upgrade comes at a time when the company is undergoing structural changes as it looks to position itself as a cannabis play. The company plans to apply a new ticker symbol and corporate name to support its new business model.

"We are confident our new status will enhance investor confidence in BANGI and enable us to more readily access institutional and individual sources of growth capital while expanding our shareholder base. However, this will be only the first step of many towards the path of becoming a fully-reporting company with the SEC," concluded Mr. Shykora.

Going forward Composite Biotechnologies will operate under the corporate name, Bangi, detailing a company focused on cannabis investments. In a special letter to shareholders, the CEO insists that they have carved one of the most lucrative niches in the cannabis sector that will act as a key driver of shareholder value going forward.

Board Boost

The company has already build-out and established a board of directors, made up of knowledgeable and most seasoned Board Members. The board is currently made up of Willard L Jackson, Co-Founder CVG Group and former U.S ambassador to Trinidad and Tobago, Dr. Neil Parsan.Dr. Parsan and Mr. Jackson are tasked with the responsibility of overseeing the company’s long-term financial strategy. In addition, they will oversee the company’s strategic business development.BANGI is also opened to pursuing mergers and acquisitions as part of its growth strategy something that the new management will oversee.

“At BANGI, our employees are systematically working every day to create value for our shareholders; obviously, there will not be news every day, but be assured that every day we are working for you,” Compass Biotechnologies in a statement.

Bottom Line

Compass Biotechnologies, now BANGI, is fresh into the cannabis sector as continues to pursue new opportunities for growth. The company has carved for itself a niche market in the multi-billion-dollar industry, where it hopes to accrue a substantial amount of shareholder value.The company is planning to become a leader in the provision of real estate assets such as cannabis farms. The business model shields the company from the hustles of coming up with cannabis products and distributing them for sale.The stock showing signs of bottoming out could as well provide early signs of renewed investor interest.We will be updating our subscribers as soon as we know more. For the latest updates on COBI, sign up below!Disclosure: We have no position in COBI and have not been compensated for this article.